ApicHope: The latest clinical results of the innovative drug deuterated benzbromarone for the treatment of gout stones were released at ACR 2025
ApicHope announced on October 29th that the latest clinical results of its innovative gout drug Deuterated Piroxicam for the treatment of gout stones will be released at ACR 2025. The clinical conclusions show that for patients with newly treated and refractory gout stones, Deuterated Piroxicam monotherapy or combination therapy with allopurinol can effectively reduce sUA, lower urate crystal burden, and achieve a high complete dissolution rate of target gout stones. Deuterated Piroxicam monotherapy or combination therapy can provide a more effective treatment option for chronic gout stone patients with poor efficacy from existing treatment regimens
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments